GlassScriptPhysician profile
Jeffrey Robert Williamson
NPI 1881641165
$5,181.69
in general payments reported to CMS, 2019-2025
48 companies · $594 in 2025
The $594 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $234 · 2021: $869 · 2022: $1,129 · 2023: $1,144 · 2024: $668 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,312 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,312.21 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $529.24 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $475.10 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $446.30 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $446.29 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $397.30 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $339.78 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $247.84 | 2019-2023 | |
| Dexcom, INC. | $209.11 | 2021-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $166.66 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $162.47 | 2019-2024 | Eliquis, Camzyos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.15 | 2022-2025 | Caplyta |
| Amgen INC. | $139.12 | 2019-2023 | Repatha, Otezla |
| Pfizer INC. | $118.69 | 2019-2025 | |
| Sanofi Pasteur INC. | $85.55 | 2019-2022 | |
| Exact Sciences Corporation | $85.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.